Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402). (Q39707401)

14 September 2017

title

Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402). (English)

1 reference

14 September 2017

0 references

1 reference

3

Jaap Goudsmit

1 reference

14 September 2017

5

Jerald Sadoff

1 reference

14 September 2017

Tom H Jin

1

1 reference

14 September 2017

Eric Tsao

series ordinal

2

1 reference

14 September 2017

Veerabadran Dheenadhayalan

series ordinal

4

1 reference

14 September 2017

language of work or name

English

0 references

publication date

2 May 2010

1 reference

14 September 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

14 September 2017

volume

28

1 reference

14 September 2017

issue

27

1 reference

14 September 2017

page(s)

4369-4375

1 reference

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Advances in tuberculosis vaccine strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Tuberculosis vaccine research: the impact of immunology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Adenovirus vector-based vaccines for human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Breathing life into protein drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Drying a tuberculosis vaccine without freezing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Interparticle forces in binary and ternary ordered powder mixes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Protein inhalation powders: spray drying vs spray freeze drying

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Needle-free epidermal powder immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

The effect of process and formulation variables on the properties of spray-dried beta-galactosidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Spray drying of an attenuated live Newcastle disease vaccine virus intended for respiratory mass vaccination of poultry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Protective effect of sucrose on spray drying of oxyhemoglobin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Comparison of particle sizing techniques in the case of inhalation dry powders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Lung Deposition of Mannitol Powder Aerosol in Healthy Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Inhalation of dry-powder mannitol increases mucociliary clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Evaluation of hydration states of protein in freeze-dried amorphous sugar matrix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

The influence of PVP incorporation on moisture-induced surface crystallization of amorphous spray-dried lactose particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Water vapor absorption into amorphous sucrose-poly(vinyl pyrrolidone) and trehalose-poly(vinyl pyrrolidone) mixtures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Dextran or hydroxyethyl starch in spray-freeze-dried trehalose/mannitol microparticles intended as ballistic particulate carriers for proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

Lung delivery of aerosolized dextran.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.059

10.1016/J.VACCINE.2010.04.059

7 January 2021

Identifiers

DOI

1 reference

release_vgzbs5op4bcupivlgqc6rt3zam

14 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vgzbs5op4bcupivlgqc6rt3zam

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference